Literature DB >> 12618129

Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho(0) cells.

Carl D Gajewski1, Michael T Lin, Merit E Cudkowicz, M Flint Beal, Giovanni Manfredi.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, which affects the anterior horn cells of the spinal cord and cortical motor neurons. A pathophysiological role for mtDNA mutations was postulated based on the finding that cybrids obtained from mitochondria of sporadic ALS patients exhibited impaired respiratory chain activities, increased free radical scavenging enzymes, and altered calcium homeostasis. To date, however, no distinct mtDNA alterations associated with ALS have been reported. Therefore, we reexamined the hypotheses that mtDNA mutations accumulate in ALS and that cybrids generated from ALS patients' blood have impaired mitochondrial respiration. Cybrid cell lines were generated from 143B osteosarcoma rho(0) cells and platelet mitochondria of sporadic ALS patients or age-matched controls. We found no statistically significant differences in mitochondrial respiration between ALS and control cybrids, even when the electron transport chain was stressed with low concentrations of respiratory chain inhibitors. Mitochondrial respiratory chain enzyme activities were also normal in ALS cybrids, and there was no increase in free radical production. Therefore, we showed that mtDNA from platelets of ALS patients was able to restore normal respiratory function in rho(0) cells, suggesting that the presence of mtDNA mutations capable of affecting mitochondrial respiration was unlikely.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618129     DOI: 10.1016/s0014-4886(02)00022-5

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Mitochondrial DNA haplogroups and amyotrophic lateral sclerosis.

Authors:  Patrick F Chinnery; Catherine Mowbray; Hannah Elliot; Joanna L Elson; Hannah Nixon; Judith Hartley; Pamela J Shaw
Journal:  Neurogenetics       Date:  2006-11-03       Impact factor: 2.660

2.  Investigation of the mitochondrial genome in patients with atypical motor neuron disease.

Authors:  Catherine Phoenix; Geoffrey A Taylor; Judith Hartley; Hannah Nixon; Paul G Ince; Pamela J Shaw; Douglass M Turnbull; Robert W Taylor
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

Review 3.  New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.

Authors:  Heather M Wilkins; Jill K Morris
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 4.  Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target?

Authors:  Sandra R Bacman; Walter G Bradley; Carlos T Moraes
Journal:  Mol Neurobiol       Date:  2006-04       Impact factor: 5.590

Review 5.  Mitochondrial dysfunction in amyotrophic lateral sclerosis - a valid pharmacological target?

Authors:  H Muyderman; T Chen
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 6.  Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies.

Authors:  Heather M Wilkins; Steven M Carl; Russell H Swerdlow
Journal:  Redox Biol       Date:  2014-04-01       Impact factor: 11.799

Review 7.  Mitochondrial DNA sequence variation and neurodegeneration.

Authors:  Michelangelo Mancuso; Massimiliano Filosto; Daniele Orsucci; Gabriele Siciliano
Journal:  Hum Genomics       Date:  2008-09       Impact factor: 4.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.